CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...
Phase 3
Warsaw, Poland and 155 other locations
(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...
Phase 3
Warsaw, Masovian Voivodeship, Poland and 167 other locations
(CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...
Phase 3
Warsaw, Poland and 229 other locations
resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease....
Phase 2
Warsaw, Poland and 69 other locations
with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma...
Phase 2, Phase 3
Wieliszew, Masovian Voivodeship, Poland and 158 other locations
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection comp...
Phase 3
Warsaw, Poland and 74 other locations
first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...
Phase 3
Warsaw, Poland and 212 other locations
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesop...
Phase 3
Warsaw, Masovian Voivodeship, Poland and 186 other locations
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzum...
Phase 3
Warsaw, Poland and 230 other locations
and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...
Phase 3
Warsaw, Poland and 185 other locations
Clinical trials
Research sites
Resources
Legal